Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

NextEdge Admin

10 Nov 2024

2 min 47 sec

DNA sequencing,Illumina,PHASE Scientific International Limited

Illumina Hong Kong Limited (Illumina), a global leader in DNA sequencing and genomics technologies, and PHASE Scientific International Limited (PHASE), a biotech company headquartered in Hong Kong, have signed a three-year Memorandum of Understanding (MoU) on November 7, at the 7th China International Import Expo. This strategic partnership focuses on advancing oncology testing in the Greater Bay Area (GBA) and aims to promote the "Healthy China" initiative by developing a consensus on Comprehensive Genomic Profiling (CGP) and increasing the adoption of Illumina's oncology solutions in the GBA.

Jenny Zheng, Senior Vice President and General Manager for Greater China at Illumina, expressed enthusiasm about collaborating with PHASE, highlighting PHASE’s R&D capabilities and commercialization success in Hong Kong, the United States, and the GBA. She noted that this partnership is an opportunity to broaden the impact of Illumina's innovative solutions within the precision health landscape.

Dr. Ricky Chiu, Chairman and CEO of PHASE, shared that this collaboration underscores Hong Kong’s strategic role as a “super-connector and super value-adder.” By combining PHASE's expertise in cancer and infectious disease detection with Illumina's advanced DNA sequencing capabilities, both companies aim to bring high-impact precision diagnostics to the GBA.

This collaboration reflects Illumina’s ongoing commitment to creating meaningful partnerships that expand access to genomic innovation globally. With Illumina’s state-of-the-art genetic and genomic analysis solutions and PHASE's patented technology for enhancing research and clinical diagnostics, the partnership seeks to advance the oncology testing market in the GBA. Together, they aim to improve public health outcomes, enhance precision diagnostics, and contribute to the region's healthcare sector development, bringing Illumina's mission of “Improving human health by unlocking the power of the genome” to life in the GBA.